The company said revenue for fiscal 2025 Q3 (ended June 30) rose 8.7% year over year to $80.7 billion, and GAAP diluted EPS was $3.52 (versus $2.42 a year earlier).

1. 01

   The company said revenue for fiscal 2025 Q3 (ended June 30) rose 8.7% year over year to $80.7 billion, and GAAP diluted EPS was $3.52 (versus $2.42 a year earlier).

2. 02

   Cencora said adjusted (non-GAAP) diluted EPS for Q3 was $4.00, up 19.8% from $3.34 a year earlier. It said adjusted operating income was $1.1 billion, up 20.6% year over year.

3. 03

   The company said it raised its adjusted diluted EPS outlook for fiscal 2025 to $15.85 to $16.00 from the prior $15.70 to $15.95 range. The company said the change reflects higher earnings growth in its U.S. Healthcare Solutions segment.

4. 04

   The company said net interest expense for Q3 was $81.8 million, an increase of $50.5 million from the year-earlier quarter. It cited its issuance of senior notes and a variable-rate term loan to help finance a portion of the January 2025 acquisition of RCA, as well as higher revolving credit facility borrowings, as factors.

Analysis scope · Filing body and confirmed press-release exhibitWe analyzed the opening part of the filing body and confirmed exhibits, within a length limit. This is not a review of other exhibits, investor presentations or the full earnings call.

AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.

Original filing

The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.